• In December 2024, anesthesiologist Dr. David Mahjoubi launched Sleepinox, a natural sleep supplement aimed at enhancing sleep quality without typical side effects of prescription drugs. Made with magnesium glycinate, valerian root, ashwagandha, and L-theanine, it offers a melatonin-free, non-addictive solution for insomnia. A liquid version is expected by late 2025.

• In January 2022, Idorsia received approval from the United States Food and Drug Administration (FDA) for QUVIVIQ 25 and 50 mg, a treatment specifically designed for adults experiencing insomnia. This medication targets individuals struggling with difficulties in sleep onset and/or maintaining sleep, offering a new therapeutic option to those affected by these common sleep issues. The FDA approval marks a significant milestone for Idorsia, expanding its portfolio of solutions for sleep-related disorders and addressing the growing need for effective treatments in this space.

In this report, the Insomnia Market has been segmented by Drug Formulation, Treatment Type, Therapy Type, Diseases Condition, and Geography.

Insomnia Market, Segmentation by Drug Formulation

The Insomnia Market has been segmented by Drug Formulation into Capsules, Tablet, and Others.

Tablets
Tablets remain the leading formulation in the insomnia treatment market, capturing about 60% of the total share. Their popularity is driven by their simplicity, precise dosing, and widespread availability in both prescription and over-the-counter options. Tablets are especially preferred for their cost-efficiency in manufacturing and ease of use, making them the go-to choice for long-term and first-line therapy for insomnia across all age groups.

Capsules
Comprising around 25% of the market, capsules are gaining traction due to their quick absorption, smooth swallowing experience, and compatibility with specialized formulations like sustained-release or herbal ingredients. They are commonly used in natural sleep aids and are favored by consumers looking for non-addictive and natural treatment options. This segment is seeing steady growth as awareness increases about alternative remedies and side-effect profiles.

Others
The “Others” category, holding close to 15%, includes innovative formats such as liquids, sprays, gummies, and sublingual strips. These options are gaining attention for their rapid onset of action, flavored delivery, and ease of administration, particularly among children, seniors, and users who struggle with swallowing pills. The segment, while smaller, is expected to expand as consumers seek more personalized and convenient sleep solutions.

Insomnia Market, Segmentation by Treatment Type

The Insomnia Market has been segmented by Treatment Type into Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others.

Nonbenzodiazepines
Nonbenzodiazepines lead the insomnia treatment market, capturing close to 38% of the total share. Often referred to as “Z-drugs”, these medications offer effective symptom relief with a lower risk of dependence and minimal residual effects. Popular choices like zolpidem and eszopiclone are widely recommended for short-term management of insomnia. Their balance of efficacy, safety, and quick onset of action has positioned them as the preferred option for both clinicians and patients.

Benzodiazepines and Antidepressants
Benzodiazepines hold about 22% of the market, largely used for short-term intervention in severe insomnia. Despite concerns regarding tolerance and dependence, they remain a viable choice in acute therapeutic scenarios. Antidepressants, which occupy around 18% of the market, are frequently prescribed when insomnia is linked with comorbid mental health conditions. Medications like trazodone are favored for their dual action in treating both mood disorders and sleep disturbances.

Orexin and Melatonin Antagonists
Emerging as innovative therapies, orexin receptor antagonists now account for approximately 10% of the market. These medications target the brain’s wake-promoting system, offering a new pathway to treat insomnia with fewer cognitive side effects. Melatonin antagonists, representing nearly 5%, appeal to users seeking natural sleep regulation. Particularly beneficial for older adults and those with jet lag or circadian rhythm issues, they are gaining ground in both prescription and OTC markets.

Devices and Others
The combined category of devices and alternative treatments represents the remaining 7% of the insomnia market. This includes wearable sleep trackers, electronic stimulation devices, and digital therapies like CBT-based apps. These non-drug options are in demand among patients looking for long-term, side-effect-free solutions. As the emphasis on behavioral health and digital wellness grows, these therapies are poised for sustained expansion.

Insomnia Market, Segmentation by Therapy Type

The Insomnia Market has been segmented by Therapy Type into Non Pharmacological Therapy and Pharmacological Therapy.

Pharmacological Therapy
Pharmacological therapy continues to dominate the insomnia treatment market, accounting for nearly 70% of total therapy usage. This category includes widely used medications like benzodiazepines, nonbenzodiazepines, and orexin receptor antagonists, all of which provide fast and effective relief for individuals suffering from insomnia. The high dependency on these medications stems from their quick onset, easy availability, and strong physician preference for managing acute and short-term cases of sleep disorders.

Non-Pharmacological Therapy
Representing around 30% of the market, non-pharmacological therapies are rapidly gaining popularity as awareness grows regarding the risks of long-term medication use. Therapies such as cognitive behavioral therapy for insomnia (CBT-I), mindfulness practices, and sleep hygiene training offer natural, side-effect-free alternatives. These approaches are increasingly being recommended as first-line treatments for chronic insomnia, particularly in healthcare settings that promote behavioral health and wellness.

Insomnia Market, Segmentation by DIseases Condition

The Insomnia Market has been segmented by DIseases Condition into Poor Quality Of Sleep, Sleep Maintenance, and Others.

Poor Quality of Sleep
Poor quality of sleep represents the largest segment in the insomnia market, contributing around 48% of diagnosed conditions. Individuals experiencing this issue often suffer from unrefreshing sleep, even after adequate time in bed, resulting in daytime drowsiness and poor concentration. Causes range from psychological stress and anxiety to environmental and lifestyle factors. As this condition impacts a large and diverse population, it continues to drive demand for both clinical interventions and at-home treatment solutions.

Sleep Maintenance
Making up nearly 35% of the market, sleep maintenance insomnia is marked by frequent nighttime awakenings and difficulty returning to sleep. It often affects older individuals and those with underlying conditions such as chronic pain or mental health disorders. This segment is seeing growing adoption of sustained-release medications, behavioral therapies, and sleep hygiene programs designed to enhance sleep continuity and duration.

Other Conditions
The remaining 17% of the market is categorized as Other, encompassing conditions like difficulty falling asleep, circadian rhythm disorders, and secondary insomnia associated with other health issues. These cases often require specialized diagnostics and tailored treatment regimens, including melatonin supplements, light therapy, and CBT-I tools. Increased public awareness and better diagnostic technologies are helping drive growth in this segment.

Insomnia Market, Segmentation by Geography

In this report, the Insomnia Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Insomnia Market Share (%), by Geographical Region, 2024

North America
North America leads the insomnia treatment market, capturing nearly 38% of the total share during the forecast period of 2021 to 2031. The region's dominance is supported by the rising prevalence of stress-related disorders, anxiety, and poor sleep hygiene. The widespread availability of advanced treatment options, strong insurance coverage, and the presence of leading pharmaceutical players contribute to high treatment uptake in the U.S. and Canada.

Europe
Accounting for approximately 28% of the insomnia market, Europe benefits from growing awareness around sleep disorders, a rising number of elderly individuals, and increased use of CBT-I and other non-drug interventions. The region is bolstered by favorable healthcare policies, especially in countries like Germany, France, and the UK, which support both medication and therapy-based approaches. The market is also influenced by proactive public health strategies promoting mental wellness.

Asia Pacific
With a market share of around 22%, the Asia Pacific region is experiencing rapid growth due to an upsurge in urban stress, expanding healthcare access, and a growing focus on mental health awareness. Countries such as China, India, and Japan are leading this regional surge, driven by the increasing adoption of both conventional and alternative treatments for insomnia. Local pharmaceutical innovation and affordable treatment options are helping penetrate underserved markets.

Middle East & Africa and Latin America
Together accounting for nearly 12%, Middle East & Africa and Latin America represent emerging regions with untapped potential. These areas are witnessing slow but steady increases in diagnosis and treatment of insomnia due to rising urbanization, healthcare infrastructure development, and growing consumer interest in wellness and lifestyle management. As awareness improves, these markets are expected to contribute more significantly to global growth in the coming years.

This report provides an in depth analysis of various factors that impact the dynamics of Insomnia Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence of sleep disorders
• Growing awareness of mental health
• Increased demand for OTC sleep aids

• Technological advances in sleep tracking - Ongoing technological advancements in sleep tracking are significantly contributing to the expansion of the Insomnia Market. Modern tools such as wearable devices, smart rings, and AI-enabled sleep monitors offer detailed insights into sleep cycles, restlessness, and sleep interruptions. These innovations support earlier detection of insomnia symptoms and allow for more precise and data-driven treatment approaches.

  The growing popularity of non-invasive, self-monitoring technologies is empowering individuals to take a proactive role in managing their sleep health. By providing real-time feedback and personalized data, these solutions enhance treatment personalization, help track progress, and improve patient engagement. As both clinical providers and consumers embrace digital health tools, sleep tracking technologies are becoming essential components of effective insomnia management strategies.

Restraints

• Side effects of prescription drugs
• Lack of long-term treatment efficacy
• Social stigma around mental disorders

• Limited availability of behavioral therapies - The limited availability of behavioral therapies, particularly Cognitive Behavioral Therapy for Insomnia (CBT-I), poses a major restraint to the growth of the Insomnia Market. Despite being a first-line treatment recommended by clinical guidelines, access to qualified CBT-I practitioners remains restricted in many regions, especially in rural and underserved areas. This gap limits the use of non-pharmacological, long-term solutions for managing insomnia.

  The shortage of trained professionals, combined with high session costs and limited insurance coverage, makes behavioral therapy inaccessible for a large portion of the population. As a result, patients often rely on medications, which may not address the root causes of insomnia and can lead to dependency or side effects. Expanding access to behavioral therapies through digital platforms and telehealth could help overcome this barrier and support more sustainable market growth.

Opportunities

• Expansion of telehealth sleep solutions
• Innovation in non-drug therapies
• Integration of AI in diagnostics

• Growing elderly population with insomnia - The growing number of elderly individuals experiencing insomnia is creating strong growth potential for the Insomnia Market. Aging naturally alters sleep patterns, often leading to shorter sleep durations, frequent awakenings, and difficulty maintaining sleep. These sleep disturbances are more common in older adults, driving greater demand for specialized treatments that address age-specific sleep challenges.

  Insomnia in the elderly is frequently linked to chronic health conditions, medication side effects, and psychological stressors, necessitating safer and more individualized treatment approaches. As geriatric care becomes a healthcare priority, there is increasing focus on integrating sleep management into overall wellness programs for older populations. This shift is encouraging the development of non-addictive, tolerable, and easy-to-use sleep interventions.

  Emerging solutions such as digital sleep therapies, wearable monitoring tools, and behavioral interventions are gaining momentum among seniors. These technologies offer accessible, low-risk options for managing sleep disorders and allow for ongoing support without the need for frequent clinical visits. As digital health literacy improves among older demographics, adoption of tech-driven insomnia management tools is expected to increase.

  With the global elderly population projected to rise significantly, targeting insomnia in this age group represents a long-term opportunity for market expansion. Companies that tailor their offerings to meet the unique needs of older adults will be well-positioned to lead innovation and address a critical gap in sleep healthcare.

Key players in Insomnia Market include :

• CURRAX PHARMACEUTICALS LLC
• EISAI CO. LTD
• Vanda Pharmaceuticals Inc.
• Merck KGaA
• Zydus Cadila
• VIATRIS INC
• MINERVA NEUROSCIENCES INC
• Sanofi
• Takeda Pharmaceutical Company Ltd
• Pfizer Inc.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis